Colombian registry of inflammatory bowel disease in pediatrics.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sarmiento Quintero Fernando, Castañeda Figueroa Ana María, Mora Quintero Diana Victoria, Sánchez Franco Claudia Patricia, Jaramillo Barberi Lina Eugenia, Prado Baquero Sergio Andrés, Suárez Urueña Marco Alberto, Pedraza Peña Andrea Natalia, Peña Hernández Stephanía, Martínez Portilla Karol Andrea, Baños Rocha Lina, Tovar Correa Luz Esthella, López Mora Diana Catalina, Pallejá López Catalina, Sánchez Hernández Diana Paola, Contreras Ramírez Mónica María, Ortiz Piedrahita Catalina, Losada Gómez Claudia Liliana, Wilches Luna Alejandra, Quimbayo Wilches Diana María, Botero Osorio Verónica, Milanés Romero Rafael, Enríquez Calvache Andrés, Vargas Sandoval Melquisedec, Medina Monroy Fernando, Laignelet Hernández Hugo, Daza Carreño Wilson, Vera Chamorro José Fernando, Carias Domínguez Ailim Margarita, Hincapié Butto Johana, Sánchez Pérez Maira Patricia, Cuadros Mendoza Carlos, Calderón Guerrero Otto, Naranjo Vergara María Mercedes, Plata García Clara Eugenia, Ramírez Urrego Luis Carlos, De Vivero Camacho Rodrigo, Paipilla Monroy Sandra Helena, Aragón Calvo Luz Eugenia, Serrano Mariastella
Аннотация
METHODS: A descriptive, longitudinal, ambispective, and multicenter observational study was conducted in children aged 0-18 years between January 1999 and December 2021. The analysis was performed based on the age of onset (Paris classification), with subdivisions for very early onset and phenotypes using the Pediatric IBD-classes algorithm. Data were collected in REDCap and analyzed with STATA 15.1.
RESULTS: A total of 209 patients were included, 54.5% male. The median age at diagnosis was 12.3 years (IQR 8.5-14.6). Phenotype distribution included: 104 (53.06%) typical ulcerative colitis (TUC), 52 (26.53%) Crohn's disease (CD), 18 (9.18%) unclassifiable IBD (U-IBD), 11 (5.61%) colonic Crohn's disease (CCD), and 11 (5.61%) atypical ulcerative colitis (AUC). The median time to diagnosis was 6.6 months, and treatment began after a median of 11.2 days. Coffee-cultivation zone 39%. Extraintestinal manifestations were reported in 43.9% of cases. Initial treatments included mesalamine ± steroids (35.86%), immunomodulators ± steroids (32%), exclusive/partial enteral nutrition (11.41%), and biologics ± immunomodulators (20.65%), which increased to 57.7% during follow-up. Relapse occurred in 53.26% of patients, while 35.32% achieved remission.
CONCLUSIONS: This registry highlights the increasing incidence of pediatric IBD in Latin America, providing valuable insights into clinical presentations, diagnostic delays, treatment strategies, and outcomes, while revealing regional and global disparities.